HPV Infections Clinical Trial
Official title:
Significance of the High-risk Hpv Viral Load
Verified date | May 2023 |
Source | Assistance Publique Hopitaux De Marseille |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of this study is to evaluate the significance of an elevated high-risk HPV (HR-HPV) viral load.
Status | Completed |
Enrollment | 149 |
Est. completion date | May 23, 2023 |
Est. primary completion date | April 24, 2014 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - The women consulting for the therapeutic care (by hysterectomy or conization) of a LIEHG or a cervical cancer (carcinoma epidermoid or adenocarcinoma) confirmed by the anatomopathologique analysis of a preoperative cervical biopsy. - The women having a normal cervix consulting for the surgical care by hysterectomy of a good-hearted pathology of the womb. The normality of the cervix will be confirmed by the anatomopathologique analysis of the detail of hysterectomy - The patients participating in this study will have to be of more than 18 years old. All the subjects will be profitable of a regime of Social Security. Exclusion Criteria: - The patients having a LIEBG - The patients incapable to receive the information enlightened on the progress and the objectives of the study - The patients not having signed enlightened assent |
Country | Name | City | State |
---|---|---|---|
France | Hopital Nord, service de gynécologie-obstétrique | Marseille |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique Hopitaux De Marseille |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Estimate the meaning of a viral load raised in HPV oncogenic | 36 months | ||
Secondary | To estimate the correlation enters the vorale load of the HPV oncogenic and the severity of the cervical hurt | 36 months | ||
Secondary | Estimate the correlation between the viral load of the HPV oncogenic and the level of transcription of the genes coding for oncoproteines E6 and E7 | 36 months | ||
Secondary | Estimate the correlation between the viral load in HPV oncogenic and the integration of the viral genome in that of the infected cells | 36 months | ||
Secondary | Estimate the correlation between a viral load raised in HPV oncogenic and a presence of HPV in the circulating blood of the infected patients | 36 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00956553 -
Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls
|
Phase 4 | |
Completed |
NCT05372016 -
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
|
Phase 3 | |
Recruiting |
NCT05027776 -
Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
|
Phase 3 | |
Suspended |
NCT00733122 -
Tolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034)
|
Phase 3 | |
Recruiting |
NCT04895020 -
Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years
|
Phase 3 | |
Recruiting |
NCT05371353 -
Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine
|
||
Completed |
NCT03900572 -
A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine
|
Phase 1 | |
Completed |
NCT00635830 -
An Open-Label, Single Dose Safety Study of Quadrivalent HPV Vaccine in Chinese Female Subjects (V501-035)
|
Phase 1 | |
Not yet recruiting |
NCT01021904 -
Primary and Secondary Prevention of Human Papillomavirus (HPV) Disease in China
|
Phase 4 | |
Completed |
NCT00378560 -
V501 Efficacy Study in Women Aged 18 to 26 (V501-027)
|
Phase 2 | |
Completed |
NCT01086709 -
Crossover Vaccination of Women Previously Randomized Into Protocol 04-C-N191
|
||
Completed |
NCT00711815 -
A Study to Identify Markers in Blood and Tissue of HPV Clearance
|
N/A | |
Completed |
NCT00834106 -
Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041)
|
Phase 3 | |
Completed |
NCT03085381 -
A Phase I Study of Quadrivalent HPV Recombinant Vaccine
|
Phase 1 | |
Completed |
NCT00847340 -
Human Papillomavirus (HPV) Genotypes in Genital Warts in Colombian Population
|
N/A | |
Completed |
NCT00411749 -
V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)
|
Phase 2 | |
Completed |
NCT00943722 -
A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)
|
Phase 3 |